Implantable cardiac monitoring and/or stimulus systems are often designed to detect individual cardiac cycles or “beats.” It is common to design these systems to identify the R-wave or QRS complex of the cardiac signal. The R-wave or QRS complex can often be distinguished by virtue of being the largest amplitude signal. A “detection profile” can be used to detect events. Some illustrative examples of R-wave or QRS complex detection are shown in U.S. Pat. No. 5,709,215 to Perttu et al., and U.S. Pat. No. 8,565,878 to Allavatam et al., the disclosures of which are incorporated herein by reference.
Various difficulties with detection can arise, including variations in amplitude from one beat to the next and poor signal to noise ratio. These issues can cause overdetection of the cardiac signal, as may happen if both the R-wave and T-wave of a single cardiac cycle are incorrectly identified as being both R-waves of two separate cardiac cycles.
The present inventor has recognized that in some instances a detection profile may avoid overdetection with a “close call.” In such cases, the present invention, in an illustrative embodiment, is designed to identify the close call and modify the manner in which at least one subsequent cardiac event is detected.
This overview is intended to provide an overview of subject matter of the present patent application. It is not intended to provide an exclusive or exhaustive explanation of the invention. The detailed description is included to provide further information about the present patent application.
In the drawings, which are not necessarily drawn to scale, like numerals may describe similar components in different views. Like numerals having different letter suffixes may represent different instances of similar components. The drawings illustrate generally, by way of example, but not by way of limitation, various embodiments discussed in the present document.
Each of the following non-limiting examples can stand on its own, or can be combined in various permutations or combinations with one or more of the other examples.
As used herein, a signal is sensed by an implantable cardiac device system, events are detected in the sensed signal, and cardiac rhythms are classified by use of the detected events. Detected events may also be referred to as detections. Classification of the cardiac rhythms may be referred to as rhythm analysis. Cardiac rhythm classification can include identification of malignant conditions, such as ventricular fibrillation or certain tachyarrhythmias, for example.
The present invention may be used in implantable monitoring or therapy systems. Implantable therapy systems make therapy/stimulus decisions in reliance upon rhythm classification, while monitoring systems make data recording decisions using rhythm classification, where applicable. Therapy systems may deliver electrical, pharmaceutical or other therapy. Some illustrative implementations of the present invention may be in pacemakers and defibrillators, though other implementations are also envisioned. Any of these systems can, if so configured and enabled, generate annunciating (audible tones or palpable vibrations) or communicating (telemetry) signals in response to rhythm classification, in addition to or as an alternative to therapy. Implantable monitoring systems may use cardiac signal analysis to determine whether data is to be recorded for later retrieval, or to take other actions such as emitting a warning or annunciating data.
Once a detected event is identified, the analysis then performs assessments to identify noise and/or overdetection as shown at 12. Noise may be identified, for example, as shown in U.S. Pat. No. 8,744,555, titled ADAPTIVE WAVEFORM APPRAISAL IN AN IMPLANTABLE CARDIAC SYSTEM, the disclosure of which is incorporated herein by reference. Overdetection may be identified, for example, as shown in U.S. Pat. Nos. 8,160,686 and 8,160,687, each titled METHODS AND DEVICES FOR ACCURATELY CLASSIFYING CARDIAC ACTIVITY, U.S. Pat. No. 8,265,737, titled METHODS AND DEVICES FOR IDENTIFYING OVERDETECTION OF CARDIAC SIGNALS, and/or US Published Patent Application No. 2012-0046563, titled METHODS AND DEVICES THAT IDENTIFY OVERDETECTION IN IMPLANTABLE CARDIAC SYSTEMS, the disclosures of which are incorporated herein by reference. Other noise identification and/or overdetection identification methods may be used instead to address malsensing and enhance the accuracy of counting of cardiac cycles.
Next, the analysis method obtains certain useful data such as rate and shape information, as shown at 14. Rate and shape information may then be used for rhythm analysis 16. If the rhythm analysis at 16 determines that therapy may be needed, a therapy decision can be made, as shown at 18. The analysis then waits for the next new detection, as shown at 20.
Illustrative methods useful in blocks 14, 16 and/or 18 are shown in the above incorporated patents and published patent applications as well as U.S. Pat. No. 6,754,528, titled APPARATUS AND METHOD OF ARRHYTHMIA DETECTION IN A SUBCUTANEOUS IMPLANTABLE CARDIOVERTER/DEFIBRILLATOR, U.S. Pat. No. 7,330,757, titled METHOD FOR DISCRIMINATING BETWEEN VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS, US Published Patent Application No. 2010-0331904, titled ADAPTIVE CONFIRMATION OF TREATABLE ARRHYTHMIA IN IMPLANTABLE CARDIAC STIMULUS DEVICES, and U.S. Pat. No. 8,588,895, titled ROBUST RATE CALCULATION IN AN IMPLANTABLE CARDIAC STIMULUS OR MONITORING DEVICE, the disclosures of which are each incorporated herein by reference. In addition to these patents and patent applications, various methods are known in the art from various commercially available implementations.
In
The detection threshold 32/34/36 relies in part on the “estimated peak” of the QRS complex, as well as a detection profile. The estimated peak is a measure of amplitude or magnitude, depending on the particulars of a given embodiment, of the cardiac signal being monitored. As the signal grows larger, so too does the estimated peak. In some examples, an estimated peak is the largest peak in a given QRS complex. In other examples, the estimated peak is an average of the largest peaks in the previous two detected cardiac events. Other measures, averages or the like may be used. The estimated peak may be used, for example, by setting the amplitude for the constant threshold period 34 at a percentage of the estimated peak, and/or by setting the beginning point of the decay period 36 to a fraction of the estimated peak.
The detection threshold is also defined by a detection profile, which defines the durations, slopes and percentages used to calculate the threshold for application to a particular cardiac signal. Illustrative detection profiles are shown in
The constant threshold period allows additional events to be detected if the cardiac signal crosses a constant threshold set to a percentage of the estimated peak. In the example, detection profile 40 applies a constant threshold, CT, of 80% of the estimated peak for a period of 200 milliseconds after the refractory period. Next, the first decay D1 of detection profile 40 has an initial threshold at 50% of the estimated peak and decays over time to an ending threshold of 37.5% of the estimated peak. The first decay D1 lasts 320 milliseconds, such that the total time to the start of the second decay D2 is 720 milliseconds. The second decay starts at 37.5% of the estimated peak and decays to a predetermined, fixed noise floor for the system. The decay periods D1, D2 of detection profile 40 illustratively use a decay constant of 400 milliseconds. Other time constants can be used instead.
A second detection profile is shown at 42. Here, detection profile 42 has the same refractory period R, with a duration of 200 milliseconds. The second detection profile 42 is less sensitive to cardiac signals than the first detection profile 40 because, at least, the constant threshold period CT1 after the refractory period has a higher threshold (95% of estimated peak, rather than 80%), and a longer duration at the higher threshold (350 milliseconds before dropping, rather than 200 milliseconds). Another example of the second detection profile 42 being less sensitive than the first detection profile 40 can be noted as decay period D1 of profile 40 is replaced with a constant threshold period CT2, beginning and ending at 50% of the estimated peak, rather than beginning at 50% and decaying to 37.5%. Finally, the second detection profile 42 is also less sensitive to cardiac signals than the first detection profile 40 because the decay period, D1 of detection profile 42, starts at 50% of the estimated peak and goes to the noise floor, while the late decay period D2 of detection profile 40 starts at 37.5% of the estimated peak instead.
The specifics of the detection profiles 40, 42 are merely illustrative of one approach and can be varied widely. Additional profiles may be provided as well, for example as shown in U.S. Pat. No. 8,565,878. Pertinent to the present invention is that multiple detection profiles are available. In some examples, a single “profile” that has multiple variants, such as multiple ways to calculate estimated peak, or a single change of one of the parameters, can be considered multiple profiles.
Returning to
It should be noted that in
Here, the detection thresholds applied after refractory periods 50, 54 are based on detection profile 40 in
The present invention expands on the concept shown in
A cardiac signal that crosses the detection threshold, in various examples, would not be deemed a close call, since it actually caused a detected event to be identified. Signals that cross the ordinary detection threshold may be analyzed as shown in
In some examples, meeting the close call amplitude threshold is sufficient to declare a close call. In other examples, the close call amplitude threshold is but one of two or more rules to be met, as further illustrated in
Starting with the detection of a cardiac event 100, the method sets a close call threshold 102. As noted above, the close call threshold may be determined as a percentage or other function of an estimated peak or of the detection threshold to be applied to the incoming cardiac signal. The method determines whether the close call threshold is determined at 104. If the close call threshold is crossed at 104, the method next confirms that a close call determination is appropriate, as shown at 106. If the close call threshold is not crossed, or if a close call determination is deemed not appropriate, the method ends at 108.
Regarding appropriateness, there are a plurality of double checks that may be performed. More than one of these double checks may be combined together. As a first matter, however, the confirmation step 106 is optional and/or omitted in some embodiments. In other embodiments, confirmation 106 includes determining that the event preceding the close call threshold crossing is “normal”, as shown at 110. Such measures of whether the preceding event is “normal” can be combined together or used separately.
Measures of normality 110 can include determining if the preceding (“first”) cardiac event is narrower than a width threshold. The width threshold may be set as desired; for near field sensing (i.e. with two electrodes inside the heart of the patient, or at least one electrode on the patient's heart), a width in the range of 40-100 milliseconds may be appropriate; for far field sensing (i.e. with two spaced electrodes not inside of or in contact with the heart), a width in the range of 60-150 milliseconds may be more appropriate. In an example, a subcutaneous-only system using widely spaced electrodes sets a normal width using a fixed threshold of 100 milliseconds. In another example, a subcutaneous-only system is configured to calculate a normal sinus rhythm template and measure the width thereof, with a width threshold set to be slightly larger than the width of the template, for example by adding 10-20 milliseconds to the template width. Examples of template formation can be found in U.S. Pat. No. 7,376,458, titled METHOD FOR DEFINING SIGNAL TEMPLATES IN IMPLANTABLE CARDIAC DEVICES, the disclosure of which is incorporated herein by reference.
Another measure of normality can be determined by comparing the preceding detected event that occurred before the close call threshold crossing to a template. Examples of template comparison can be found in U.S. Pat. No. 7,477,935, titled METHOD AND APPARATUS FOR BEAT ALIGNMENT AND COMPARISON, and U.S. Pat. No. 8,160,687, titled METHODS AND DEVICES FOR ACCURATELY CLASSIFYING CARDIAC ACTIVITY, the disclosure of which is incorporated herein by reference. Templates can be stored, static templates, or may be dynamic templates which change over time or which each newly detected event/beat.
Another way to confirm whether it is appropriate to declare a close call is to determine whether the peak causing the close call threshold crossing is likely to be a T-wave, as shown at 112. In one example, such confirmation is performed by applying a known formula for determining a QT interval. Examples include:
Bazett's formula:
QT(Exp)=QT*√{square root over (RR)}
Fridericia's formula:
And the Sagie et al. regression formula:
QT(Exp)=QT+A*(RR−1)
Sagie et al. found A=0.154. In these formulas, “RR” stands for the interval between two R-waves, and QT stands for the interval from the Q wave peak, starting the QRS complex, to the T-wave peak in a given cardiac cycle.
In another example, finding that the close call threshold was crossed by a likely T-wave may be determined by confirming that the width of the peak that causes the close call is greater than the width of the preceding detected cardiac event by some margin. For example, the peak associated with the close call threshold crossing would have to be at least 40 milliseconds wider than the preceding detected cardiac event.
In certain examples, two or more confirmation criteria are combined, for example, a combination of the “close call” being wider than the preceding detected event and occurring at an expected time as determined by one of the above formulas for predicting QT interval. Other combinations of any of these criteria may be used in additional alternative examples.
If the confirmation step 106 is passed, the method then modifies the selection of detection profile. In an example, a detection profile is selected for use in the next “N” detected events which is less sensitive than one or more other detection profiles. For example, profile 42 in
As noted in
The present invention may find application in a subcutaneous-only system as illustrated in
The illustrative system shown in
The system in
Communication for either of the systems in
The canisters in
The location of system implant may vary. For example, the system shown is a subcutaneous-only system located on the anterior and lateral chest between the skin and ribcage of the patient. Other subcutaneous only systems (including systems without a lead 204, with multiple leads 204, or an array in place of lead 204) may be used with other anterior only placements and/or anterior-posterior, posterior only, left-right, etc. locations, including, for example, locations noted in U.S. Pat. Nos. 6,647,292, 6,721,597, 7,149,575, 7,194,302, each of which is incorporated herein by reference, and other locations as well. Subcutaneous placement can include any location between the skin and ribcage, including sub-muscular. A subcutaneous-only defibrillator may also be used in combination with a fully intracardiac device such as a seed pacer, for example, the Nanostim™ leadless pacemaker or Micra™ transcatheter pacing system.
Other systems may include one or more transvenous leads or epicardial leads/electrodes, and may use different canister implant locations, such as placing the canister in a higher pectoral position closer to the clavicle for closer venous access, or abdominal placement. Illustrative transvenous systems include single chamber, dual chamber and biventricular systems. A fully intravenous system has also been proposed. Additional or other coatings or materials than those noted above may be used, particularly for epicardial, transvenous or intravenous systems, leads and canisters.
Various alternatives and details for these designs, materials and implantation approaches are known to those skilled in the art. Commercially available systems in which the above methods can be performed or which may be configured to perform such methods are known including the Boston Scientific Teligen™ ICD and S-ICD™ System, Medtronic Concerto™ and Virtuoso™ systems, and St. Jude Medical Promote™ RF and Current™ RF systems. Such platforms include numerous examples and alternatives for the operational circuitry, battery, canister, lead, and other system elements.
Yet another illustrative method is shown in the block diagram of
Next, as shown at 304, the PRP is (optionally) compared to a previous PRP, or an average of several previous PRPs. This step 304 may be useful to ensure that the adjustments performed in block 308 are only performed if the detected signal is relatively consistent in its amplitude components. Thus, if the PRP is similar to previous PRP value(s), as indicated at 306, then the detection profile for use in the next cardiac cycle is adjusted to use the PRP plus a margin, as shown at 308, during the window for PRP detection.
Thus, referring to
Going back through the drawing, if the PRP is not similar to the prior PRP value(s), then the dissimilar path 310 is followed, and an ordinary detection threshold setup, as described in other patents and noted above, may be used, as shown at 312. As noted previously, block 304 may be bypassed, if desired, such that the method simply jumps to block 308. Alternative, some other “stable signal” rule can be used, for example looking at R-wave peaks themselves rather than the signal in a PRP window to determine similarity.
A first non-limiting example takes the form of an implantable cardiac system including a plurality of electrodes coupled to operational circuitry configured to analyze cardiac signals, the system comprising detecting means for detecting a first cardiac event by the application of a detection profile which defines a detection threshold, the detecting means configured to use at least first and second detection profiles, with the second detection profile having lesser sensitivity to cardiac signals than the first detection profile. Examples of detecting means are shown by
The first non-limiting example is characterized in that the system further includes close call means for determining whether a close call has occurred in which the cardiac signal nearly caused a likely overdetection but did not, the close call means adapted to set a close call threshold relative to the detection threshold and determining whether a cardiac signal associated with the first cardiac event crosses the close call threshold without crossing the detection threshold following the first cardiac event. The close call means is illustrated in
A second non-limiting example takes the form of a system as in the first non-limiting example, wherein: the detection means is configured to detect a second cardiac event following the first cardiac event; the close call means is configured to analyze the time period between the first cardiac event and the second cardiac event to determine whether a close call has occurred and, if so, the detection means is configured to respond to the close call means by selecting the second detection profile for use after the second cardiac event is detected until at least a third cardiac event has taken place.
A third non-limiting example takes the form of a system as in either the first or second non-limiting examples, wherein the close call means comprises confirmation means to confirm that it is appropriate to declare a close call if the close call threshold is crossed at a time, relative to the first cardiac event, when it is likely that a T-wave would occur. A fourth non-limiting example takes the form of a system as in the third non-limiting example, wherein the confirmation means is configured to use an accepted formula for determining a QT Interval to determine whether the close call threshold is crossed at a time when it is likely that a T-wave could occur. A fifth non-limiting example takes the form of a system as in the fourth non-limiting example, wherein the accepted formula is one of Fridericia's formula, Bazett's formula, or the Sagie et al. regression formula.
A sixth non-limiting example takes the form of a system as in the third non-limiting example, wherein the confirmation means further comprises means to determine whether the width of the first cardiac event is below a width threshold such that, if the width of the first cardiac event is narrower than the width threshold, and the close call threshold is crossed at a time when it is likely that a T-wave would occur, then it is found appropriate to declare a close call.
A seventh non-limiting example takes the form of a system as in the third non-limiting example, wherein the confirmation means further comprises matching means to determine whether the first cardiac event matches a template, wherein the confirmation means will only confirm that it is appropriate to declare a close call if the matching means finds a match between the first cardiac event and the template.
An eighth non-limiting example takes the form of a system as in either of the first or second non-limiting examples, wherein the close call means comprises confirmation means to confirm that it is appropriate to declare a close call if the width of the first cardiac event is narrower than a width threshold. A ninth non-limiting example takes the form of a system as in either of the first or second non-limiting examples, wherein the close call means comprises confirmation means to confirm that it is appropriate to declare a close call if the first cardiac event matches a template.
A tenth non-limiting example takes the form of a system as in any of the first nine non-limiting examples, which is further configured such that each cardiac event is intended to be a single cardiac cycle or beat. An eleventh non-limiting example takes the form of a system as in any of the first ten non-limiting examples, further comprising rhythm analysis means for determining whether a cardiac condition warranting therapy is occurring. A twelfth non-limiting example takes the form of a system as in any of the first eleven non-limiting examples, further comprising therapy means for delivering therapy if a cardiac condition warranting therapy is occurring.
A thirteenth non-limiting example takes the form of a system as in any of the first twelve non-limiting examples, wherein the system is configured as an transvenous implantable cardiac therapy system. A fourteenth non-limiting example takes the form of a system as in any of the first twelve non-limiting examples, wherein the system is configured as a subcutaneous implantable cardiac therapy system. A fifteenth non-limiting example takes the form of a system as in any of the first ten non-limiting examples, wherein the system is an implantable cardiac monitor.
A sixteenth non-limiting example takes the form of an implantable cardiac system comprising a plurality of electrodes coupled to operational circuitry configured to analyze cardiac signals, wherein: the operational circuitry is configured detect to cardiac events by the application of a detection threshold to a cardiac signal received from the electrodes, the detection threshold being defined by a detection profile selected from at least first and second detection profiles, with the second detection profile having lesser sensitivity to cardiac signals than the first detection profile; the operational circuitry is configured to detect a first cardiac event and determine whether a close call has occurred by applying close call rules; the operational circuitry is configured such that the close call rules comprise a first rule relying on a close call threshold defined relative to the detection threshold such that the first rule is met if the cardiac signal following the first cardiac event crosses the close call threshold without crossing the detection threshold; and the operational circuitry is configured to select the second detection profile for use in detecting at least one cardiac event after the first cardiac event if it determines that a close call has occurred in which at least the first rule has been met.
A seventeenth non-limiting example takes the form of a system as in the sixteenth non-limiting example, wherein the operational circuitry is configured to detect a second cardiac event after the first cardiac event and, if a close call has occurred between the first and second cardiac events, to apply the second detection profile following the second cardiac event in order to detect a third cardiac event after the second cardiac event, wherein each cardiac event is intended to be a single cardiac cycle or beat.
An eighteenth non-limiting example takes the form of a system as in the sixteenth or seventeenth non-limiting examples, wherein the operational circuitry is configured such that the close call rules comprise a second rule to determine whether, if the close call threshold is crossed after the first cardiac event, the time at which such crossing occurs corresponds to a likely T-wave would occur using an accepted formula for determining a QT Interval and assuming the first cardiac event represents a QRS complex, wherein if the close call threshold is crossed and the timing of the crossing corresponds to a likely T-wave, then it is found appropriate to declare a close call. A nineteenth non-limiting example takes the form of a system as in the eighteenth non-limiting example, wherein the accepted formula is selected from the group consisting of Fridericia's formula, Bazett's formula, or the Sagie et al. regression formula.
A twentieth non-limiting example takes the form of a system as in the sixteenth or seventeenth non-limiting examples, wherein the operational circuitry is configured such that the close call rules comprise a second rule to determine whether the first cardiac event has a width that is narrower than width threshold such that, if the close call threshold is crossed, and the width of the first cardiac event is narrower than the width threshold, then it is found appropriate to declare a close call.
A twenty-first non-limiting example takes the form of a system as in the sixteenth or seventeenth non-limiting examples, wherein the operational circuitry is configured such that the close call rules comprise a second rule to determine whether the first cardiac event matches a template, wherein if the close call threshold is crossed and the first cardiac event matches the template, then it is found appropriate to declare a close call.
A twenty-second non-limiting example takes the form of a method of operation in an implantable cardiac system comprising a plurality of electrodes coupled to operational circuitry configured to analyze cardiac signals, the method comprising: the operational circuitry detecting a first cardiac event by comparing a cardiac signal received from the electrodes to a detection threshold, the detection threshold being defined by a detection profile chosen from at least first and second detection profiles, with the second detection profile having lesser sensitivity to cardiac signals than the first detection profile; the operational circuitry detecting a close call after the first cardiac event, in which the close call is detected by applying a set of close call rules including a first rule in which: the operational circuitry defines a detection threshold to apply after the first cardiac event is detected; the operational circuitry defines a close call threshold below the detection threshold; and the operational circuitry determines that the close call threshold has been crossed without the detection threshold being crossed; and the operational circuitry determining that a close call has occurred in response to the set of close call rules being met, including finding that at least the first rule has been met, and, in response to determining that a close call has occurred, selects the second detection profile for use in detecting at least one cardiac event.
A twenty-third non-limiting example takes the form of a method as in the twenty-second non-limiting example, further comprising: the operational circuitry detecting a second cardiac event after the first cardiac event; the operational circuitry determining that the close call occurred between the first and second cardiac events; and in response to the close call, the operational circuitry applying the second detection profile following the second cardiac event in order to detect a third cardiac event after the second cardiac event; wherein each cardiac event is intended to be a single cardiac cycle or beat.
A twenty-fourth non-limiting example takes the form of a method as in either of the twenty-second or twenty-third non-limiting examples, further comprising the operational circuitry analyzing a second rule in the close call rules including: determining that the close call threshold is crossed after the first cardiac event; analyzing a time at which the crossing of the close call threshold occurred to determine whether it corresponds to a likely T-wave using an accepted formula for determining a QT Interval and assuming the first cardiac event represents a QRS complex; wherein the step of the operational circuitry detecting the close call includes determining that the second rule has been met by finding that the crossing of the close call threshold corresponds to a likely T-wave.
A twenty-fifth non-limiting example takes the form of a method as in the twenty-fourth non-limiting example wherein the operational circuitry is configured such that the accepted formula is selected from the group consisting of Fridericia's formula, Bazett's formula, or the Sagie et al. regression formula.
A twenty-sixth non-limiting example takes the form of a method as in either of the twenty-second or twenty-third non-limiting examples, further comprising the operational circuitry analyzing a second rule in the close call rules including: determining a width of the first cardiac event; and comparing the width of the first cardiac event to a width threshold; and wherein the step of the operational circuitry detecting the close call includes determining that the second rule has been met by finding that the width of the first cardiac event is narrower than the width threshold.
A twenty-seventh non-limiting example takes the form of a method as in either of the twenty-second or twenty-third non-limiting examples, further comprising the operational circuitry analyzing a second rule in the close call rules including comparing the first cardiac event to a template; and wherein the step of the operational circuitry detecting the close call includes determining that the second rule has been met by finding that the first cardiac event matches the template.
A twenty-eighth non-limiting example takes the form of a method of cardiac event detection in an implantable cardiac system having a plurality of electrodes and operational circuitry for the system coupled to the plurality of electrodes, the method comprising: the operational circuitry receiving a signal from the plurality of electrodes; and the operational circuitry detecting a plurality of cardiac events by comparing the signal to a detection threshold defined by a detection profile, the detection profile having: a refractory period applied initially after a cardiac event is detected during which additional cardiac events cannot be detected followed by one or more detection periods during which additional cardiac events can be detected if the cardiac signal crosses the detection threshold; wherein for at least one of the detection periods applied after a refractory period of a first of the plurality of detected cardiac events, the detection threshold is set by observing a signal peak during a corresponding detection period applied after a second of the plurality of detected cardiac events and adding a margin; and wherein the first of the plurality of detected cardiac events follows the second of the plurality of detected cardiac events.
A twenty-ninth non-limiting example takes the form of a method as in the twenty-eighth non-limiting example, wherein the detection threshold during the at least one detection period is set by observing the signal peak during the corresponding detection period after the second detected event and adding a margin only if the signal peak during the corresponding detection period after the second detected event also matches a signal peak during the corresponding detection period after a third detected event.
A thirtieth non-limiting example takes the form of an implantable cardiac system having a plurality of electrodes and operational circuitry for the system coupled to the plurality of electrodes, in which the operational circuitry is configured to perform the method of any of the twenty-second to twenty-ninth non-limiting examples.
Each of these non-limiting examples can stand on its own, or can be combined in various permutations or combinations with one or more of the other examples.
The above detailed description includes references to the accompanying drawings, which form a part of the detailed description. The drawings show, by way of illustration, specific embodiments in which the invention can be practiced. These embodiments are also referred to herein as “examples.” Such examples can include elements in addition to those shown or described. However, the present inventors also contemplate examples in which only those elements shown or described are provided. Moreover, the present inventors also contemplate examples using any combination or permutation of those elements shown or described (or one or more aspects thereof), either with respect to a particular example (or one or more aspects thereof), or with respect to other examples (or one or more aspects thereof) shown or described herein.
In the event of inconsistent usages between this document and any documents so incorporated by reference, the usage in this document controls.
In this document, the terms “a” or “an” are used, as is common in patent documents, to include one or more than one, independent of any other instances or usages of “at least one” or “one or more.” In this document, the term “or” is used to refer to a nonexclusive or, such that “A or B” includes “A but not B,” “B but not A,” and “A and B,” unless otherwise indicated. In this document, the terms “including” and “in which” are used as the plain-English equivalents of the respective terms “comprising” and “wherein.” Also, in the following claims, the terms “including” and “comprising” are open-ended, that is, a system, device, article, composition, formulation, or process that includes elements in addition to those listed after such a term in a claim are still deemed to fall within the scope of that claim. Moreover, in the following claims, the terms “first,” “second,” and “third,” etc. are used merely as labels, and are not intended to impose numerical requirements on their objects.
Method examples described herein can be machine or computer-implemented at least in part. Some examples can include a computer-readable medium or machine-readable medium encoded with instructions operable to configure an electronic device to perform methods as described in the above examples. An implementation of such methods can include code, such as microcode, assembly language code, a higher-level language code, or the like. Such code can include computer readable instructions for performing various methods. The code may form portions of computer program products. Further, in an example, the code can be tangibly stored on one or more volatile, non-transitory, or non-volatile tangible computer-readable media, such as during execution or at other times. Examples of these tangible computer-readable media can include, but are not limited to, hard disks, removable magnetic disks, removable optical disks (e.g., compact disks and digital video disks), magnetic cassettes, memory cards or sticks, random access memories (RAMs), read only memories (ROMs), and the like.
The above description is intended to be illustrative, and not restrictive. For example, the above-described examples (or one or more aspects thereof) may be used in combination with each other. Other embodiments can be used, such as by one of ordinary skill in the art upon reviewing the above description. The Abstract is provided to comply with 37 C.F.R. § 1.72(b), to allow the reader to quickly ascertain the nature of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims. Also, in the above Detailed Description, various features may be grouped together to streamline the disclosure. This should not be interpreted as intending that an unclaimed disclosed feature is essential to any claim. Rather, inventive subject matter may lie in less than all features of a particular disclosed embodiment. Thus, the following claims are hereby incorporated into the Detailed Description as examples or embodiments, with each claim standing on its own as a separate embodiment, and it is contemplated that such embodiments can be combined with each other in various combinations or permutations. The scope of the invention should be determined with reference to the appended claims, along with the full scope of equivalents to which such claims are entitled.
The present application is a continuation of U.S. application Ser. No. 14/815,267, filed Jul. 31, 2015, which claims the benefit of and priority to U.S. Provisional Application No. 62/037,288, filed on Aug. 14, 2014, the disclosure of which is incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
4184493 | Langer et al. | Jan 1980 | A |
4300567 | Kolenik et al. | Nov 1981 | A |
4407288 | Langer et al. | Oct 1983 | A |
4450527 | Sramek | May 1984 | A |
4457315 | Bennish | Jul 1984 | A |
4589420 | Adams et al. | May 1986 | A |
4595009 | Leinders | Jun 1986 | A |
4679144 | Cox et al. | Jul 1987 | A |
4693253 | Adams | Sep 1987 | A |
4750494 | King | Jun 1988 | A |
4779617 | Whigham | Oct 1988 | A |
4940054 | Grevis et al. | Jul 1990 | A |
4979110 | Albrecht et al. | Dec 1990 | A |
4989602 | Sholder et al. | Feb 1991 | A |
5000189 | Throne et al. | Mar 1991 | A |
5105810 | Collins et al. | Apr 1992 | A |
5117824 | Keimel et al. | Jun 1992 | A |
5184616 | Weiss | Feb 1993 | A |
5193535 | Bardy et al. | Mar 1993 | A |
5215098 | Steinhaus et al. | Jun 1993 | A |
5217021 | Steinhaus et al. | Jun 1993 | A |
5240009 | Williams | Aug 1993 | A |
5271411 | Ripley et al. | Dec 1993 | A |
5273049 | Steinhaus et al. | Dec 1993 | A |
5280792 | Leong et al. | Jan 1994 | A |
5299119 | Kraf et al. | Mar 1994 | A |
5313953 | Yomtov et al. | May 1994 | A |
5331966 | Bennett et al. | Jul 1994 | A |
5339820 | Henry et al. | Aug 1994 | A |
5342402 | Olson et al. | Aug 1994 | A |
5342407 | Dahl et al. | Aug 1994 | A |
5351686 | Steuer et al. | Oct 1994 | A |
5351696 | Riff et al. | Oct 1994 | A |
5376104 | Sakai et al. | Dec 1994 | A |
5400795 | Murphy et al. | Mar 1995 | A |
5423326 | Wang et al. | Jun 1995 | A |
5447519 | Peterson | Sep 1995 | A |
5464431 | Adams et al. | Nov 1995 | A |
5470342 | Mann et al. | Nov 1995 | A |
5486199 | Kim et al. | Jan 1996 | A |
5513644 | McClure et al. | May 1996 | A |
5522852 | White et al. | Jun 1996 | A |
5534019 | Paspa | Jul 1996 | A |
5545186 | Olson et al. | Aug 1996 | A |
5558098 | Fain | Sep 1996 | A |
5564430 | Jacobson et al. | Oct 1996 | A |
5607455 | Armstrong | Mar 1997 | A |
5620466 | Haefner et al. | Apr 1997 | A |
5658317 | Haefner et al. | Aug 1997 | A |
5676690 | Norén | Oct 1997 | A |
5685315 | McClure et al. | Nov 1997 | A |
5702425 | Wickham | Dec 1997 | A |
5709215 | Perttu et al. | Jan 1998 | A |
5755738 | Kim et al. | May 1998 | A |
5776168 | Gunderson | Jul 1998 | A |
5779645 | Olson et al. | Jul 1998 | A |
5817134 | Greenhut et al. | Oct 1998 | A |
5827197 | Bocek et al. | Oct 1998 | A |
5857977 | Caswell et al. | Jan 1999 | A |
5876350 | Lo et al. | Mar 1999 | A |
5891048 | Nigam et al. | Apr 1999 | A |
5991657 | Kim | Nov 1999 | A |
6029086 | Kim et al. | Feb 2000 | A |
6041251 | Kim et al. | Mar 2000 | A |
6047210 | Kim et al. | Apr 2000 | A |
6052617 | Kim | Apr 2000 | A |
6058328 | Levine et al. | May 2000 | A |
6095987 | Shmulewitz et al. | Aug 2000 | A |
6115628 | Stadler et al. | Sep 2000 | A |
6144879 | Gray | Nov 2000 | A |
6148230 | KenKnight | Nov 2000 | A |
6223078 | Marcovecchio | Apr 2001 | B1 |
6230055 | Sun et al. | May 2001 | B1 |
6236882 | Lee et al. | May 2001 | B1 |
6240313 | Esler | May 2001 | B1 |
6266554 | Hsu et al. | Jul 2001 | B1 |
6280462 | Hauser et al. | Aug 2001 | B1 |
6308095 | Hsu et al. | Oct 2001 | B1 |
6334071 | Lu | Dec 2001 | B1 |
6377844 | Graen | Apr 2002 | B1 |
6381493 | Stadler et al. | Apr 2002 | B1 |
6393316 | Gillberg et al. | May 2002 | B1 |
6397100 | Stadler et al. | May 2002 | B2 |
6411844 | Kroll et al. | Jun 2002 | B1 |
6438410 | Hsu et al. | Aug 2002 | B2 |
6449503 | Hsu | Sep 2002 | B1 |
6493579 | Gilkerson et al. | Dec 2002 | B1 |
6493584 | Lu | Dec 2002 | B1 |
6505068 | Bonnet et al. | Jan 2003 | B2 |
6516225 | Florio | Feb 2003 | B1 |
6561984 | Turcott | May 2003 | B1 |
6567691 | Stadler | May 2003 | B1 |
6574505 | Warren | Jun 2003 | B1 |
6575912 | Turcott | Jun 2003 | B1 |
6587720 | Hsu et al. | Jul 2003 | B2 |
6625490 | McClure | Sep 2003 | B1 |
6643549 | Bradley et al. | Nov 2003 | B1 |
6647292 | Bardy et al. | Nov 2003 | B1 |
6684100 | Sweeney et al. | Jan 2004 | B1 |
6699200 | Cao et al. | Mar 2004 | B2 |
6708058 | Kim et al. | Mar 2004 | B2 |
6708062 | Ericksen et al. | Mar 2004 | B2 |
6721597 | Bardy et al. | Apr 2004 | B1 |
6728572 | Hsu et al. | Apr 2004 | B2 |
6731978 | Olson et al. | May 2004 | B2 |
6745068 | Koyrakh et al. | Jun 2004 | B2 |
6754528 | Bardy et al. | Jun 2004 | B2 |
6889079 | Bocek et al. | May 2005 | B2 |
6892092 | Palreddy et al. | May 2005 | B2 |
6909916 | Spinelli et al. | Jun 2005 | B2 |
6950702 | Sweeney | Sep 2005 | B2 |
7016730 | Ternes | Mar 2006 | B2 |
7020523 | Lu et al. | Mar 2006 | B1 |
7027856 | Zhou et al. | Apr 2006 | B2 |
7027858 | Cao et al. | Apr 2006 | B2 |
7027862 | Dahl et al. | Apr 2006 | B2 |
7031764 | Schwartz et al. | Apr 2006 | B2 |
7062314 | Zhu et al. | Jun 2006 | B2 |
7062315 | Koyrakh et al. | Jun 2006 | B2 |
7062322 | Stadler et al. | Jun 2006 | B2 |
7076289 | Sarkar et al. | Jul 2006 | B2 |
7085599 | Kim et al. | Aug 2006 | B2 |
7103412 | Kroll | Sep 2006 | B1 |
7117035 | Wagner et al. | Oct 2006 | B2 |
7123954 | Narayan et al. | Oct 2006 | B2 |
7149575 | Ostroff et al. | Dec 2006 | B2 |
7155282 | Min | Dec 2006 | B1 |
7162301 | Kim et al. | Jan 2007 | B2 |
7167747 | Gunderson et al. | Jan 2007 | B2 |
7184815 | Kim et al. | Feb 2007 | B2 |
7184818 | Kim et al. | Feb 2007 | B2 |
7191004 | Kim et al. | Mar 2007 | B2 |
7194302 | Bardy et al. | Mar 2007 | B2 |
7218966 | Haefner | May 2007 | B2 |
7236819 | Brockway et al. | Jun 2007 | B2 |
7248921 | Palreddy et al. | Jul 2007 | B2 |
7266409 | Gunderson | Sep 2007 | B2 |
7283863 | Gunderson et al. | Oct 2007 | B2 |
7302294 | Kamath et al. | Nov 2007 | B2 |
7330757 | Ostroff et al. | Feb 2008 | B2 |
7346392 | KenKnight | Mar 2008 | B2 |
7376458 | Palreddy et al. | May 2008 | B2 |
7379772 | Bardy et al. | May 2008 | B2 |
7386342 | Falkenberg et al. | Jun 2008 | B1 |
7392085 | Warren et al. | Jun 2008 | B2 |
7444182 | Ostroff et al. | Oct 2008 | B2 |
7447540 | Nabutovsky et al. | Nov 2008 | B1 |
7467009 | Palreddy et al. | Dec 2008 | B2 |
7477935 | Palreddy et al. | Jan 2009 | B2 |
7496408 | Ghanem et al. | Feb 2009 | B2 |
7496409 | Greenhut et al. | Feb 2009 | B2 |
7499750 | Haefner et al. | Mar 2009 | B2 |
7522959 | Hauser et al. | Apr 2009 | B2 |
7546159 | Nabutovsky et al. | Jun 2009 | B1 |
7555335 | Kamath et al. | Jun 2009 | B2 |
7559900 | Gillberg | Jul 2009 | B2 |
7567835 | Gunderson et al. | Jul 2009 | B2 |
7570997 | Lovett et al. | Aug 2009 | B2 |
7593771 | Yonce et al. | Sep 2009 | B2 |
7623913 | Phillips | Nov 2009 | B2 |
7623916 | Julian | Nov 2009 | B2 |
7655014 | Ko et al. | Feb 2010 | B2 |
7682316 | Anderson et al. | Mar 2010 | B2 |
7684864 | Olson et al. | Mar 2010 | B2 |
7715906 | Krause et al. | May 2010 | B2 |
7734345 | Cinbis | Jun 2010 | B2 |
7761142 | Ghanem et al. | Jul 2010 | B2 |
7774049 | Ghanem et al. | Aug 2010 | B2 |
7783354 | Gunderson | Aug 2010 | B2 |
7792571 | Sweeney et al. | Sep 2010 | B2 |
7797036 | Zhang et al. | Sep 2010 | B2 |
7801594 | Higham | Sep 2010 | B1 |
7865233 | Haefner | Jan 2011 | B2 |
7894894 | Stadler et al. | Feb 2011 | B2 |
7904142 | Kim et al. | Mar 2011 | B2 |
7904153 | Greenhut et al. | Mar 2011 | B2 |
7907993 | Ghanem et al. | Mar 2011 | B2 |
8160686 | Allavatam et al. | Apr 2012 | B2 |
8160687 | Warren et al. | Apr 2012 | B2 |
8160697 | Warren et al. | Apr 2012 | B2 |
8265737 | Warren et al. | Sep 2012 | B2 |
8265749 | Allavatam et al. | Sep 2012 | B2 |
8494630 | Palreddy et al. | Jul 2013 | B2 |
8565878 | Allavatam et al. | Oct 2013 | B2 |
8588895 | Sanghera et al. | Nov 2013 | B2 |
8588896 | Allavatam et al. | Nov 2013 | B2 |
8600489 | Warren et al. | Dec 2013 | B2 |
8626280 | Allavatam et al. | Jan 2014 | B2 |
8744555 | Allavatam et al. | Jun 2014 | B2 |
20030204215 | Gunderson et al. | Oct 2003 | A1 |
20040049120 | Cao et al. | Mar 2004 | A1 |
20040215239 | Favet et al. | Oct 2004 | A1 |
20040215240 | Lovett et al. | Oct 2004 | A1 |
20040220628 | Wagner | Nov 2004 | A1 |
20040230229 | Lovett et al. | Nov 2004 | A1 |
20050107838 | Lovett et al. | May 2005 | A1 |
20050131464 | Heinrich et al. | Jun 2005 | A1 |
20050154421 | Ousdigian | Jul 2005 | A1 |
20060116595 | Palreddy et al. | Jun 2006 | A1 |
20060116725 | Palreddy et al. | Jun 2006 | A1 |
20060122676 | Ko et al. | Jun 2006 | A1 |
20060167502 | Haefner | Jul 2006 | A1 |
20060167503 | Warren et al. | Jul 2006 | A1 |
20060167504 | Warren et al. | Jul 2006 | A1 |
20060235476 | Gunderson et al. | Oct 2006 | A1 |
20060241701 | Markowitz et al. | Oct 2006 | A1 |
20070032829 | Ostroff | Feb 2007 | A1 |
20070049975 | Cates et al. | Mar 2007 | A1 |
20070135847 | Kenknight | Jun 2007 | A1 |
20070142736 | Cazares et al. | Jun 2007 | A1 |
20070156190 | Cinbis | Jul 2007 | A1 |
20070179539 | Degroot et al. | Aug 2007 | A1 |
20070179540 | Stegemann et al. | Aug 2007 | A1 |
20070232944 | Ghanem et al. | Oct 2007 | A1 |
20070232945 | Kleckner et al. | Oct 2007 | A1 |
20070232948 | Stadler et al. | Oct 2007 | A1 |
20070233198 | Ghanem et al. | Oct 2007 | A1 |
20070276445 | Sanghera et al. | Nov 2007 | A1 |
20080015647 | Palreddy et al. | Jan 2008 | A1 |
20080077030 | Ostroff et al. | Mar 2008 | A1 |
20080082014 | Cao et al. | Apr 2008 | A1 |
20080086174 | Libbus et al. | Apr 2008 | A1 |
20080091242 | Kamath et al. | Apr 2008 | A1 |
20080132965 | Ostroff et al. | Jun 2008 | A1 |
20080161870 | Gunderson | Jul 2008 | A1 |
20080172098 | Gunderson | Jul 2008 | A1 |
20080183085 | van Oort et al. | Jul 2008 | A1 |
20080188901 | Sanghera et al. | Aug 2008 | A1 |
20080215110 | Gunderson | Sep 2008 | A1 |
20080221632 | Bardy et al. | Sep 2008 | A1 |
20080228093 | Dong et al. | Sep 2008 | A1 |
20080243200 | Scinicariello et al. | Oct 2008 | A1 |
20080262559 | Zhang et al. | Oct 2008 | A1 |
20080275516 | Ghanem et al. | Nov 2008 | A1 |
20080275517 | Ghanem et al. | Nov 2008 | A1 |
20080275519 | Ghanem et al. | Nov 2008 | A1 |
20080275521 | Warren et al. | Nov 2008 | A1 |
20080288009 | Kim et al. | Nov 2008 | A1 |
20090036788 | Nabutovsky et al. | Feb 2009 | A1 |
20090043352 | Brooke et al. | Feb 2009 | A1 |
20090054796 | Sanghera et al. | Feb 2009 | A1 |
20090054938 | Ostroff et al. | Feb 2009 | A1 |
20090093731 | Palreddy et al. | Apr 2009 | A1 |
20090156957 | Linder et al. | Jun 2009 | A1 |
20090157128 | Seim et al. | Jun 2009 | A1 |
20090157132 | Linder et al. | Jun 2009 | A1 |
20090157137 | Gilkerson et al. | Jun 2009 | A1 |
20090187227 | Palreddy et al. | Jul 2009 | A1 |
20090228057 | Allavatam et al. | Sep 2009 | A1 |
20090240157 | Lian et al. | Sep 2009 | A1 |
20090240300 | Lian et al. | Sep 2009 | A1 |
20090259271 | Allavatam | Oct 2009 | A1 |
20100004713 | Warren et al. | Jan 2010 | A1 |
20100094369 | Allavatam et al. | Apr 2010 | A1 |
20100152798 | Sanghera et al. | Jun 2010 | A1 |
20100152799 | Sanghera et al. | Jun 2010 | A1 |
20100185109 | Zhang et al. | Jul 2010 | A1 |
20100331904 | Warren et al. | Dec 2010 | A1 |
20110098585 | Warren et al. | Apr 2011 | A1 |
20110098775 | Allavatam et al. | Apr 2011 | A1 |
20120046563 | Allavatam et al. | Feb 2012 | A1 |
20130006085 | Allavatam et al. | Jan 2013 | A1 |
Number | Date | Country |
---|---|---|
1819855 | Aug 2006 | CN |
1829554 | Sep 2006 | CN |
1915166 | Feb 2007 | CN |
1985750 | Jun 2007 | CN |
101065059 | Oct 2007 | CN |
0554208 | Aug 1993 | EP |
1774907 | Apr 2007 | EP |
2313153 | Apr 2012 | EP |
2455132 | May 2012 | EP |
2006523505 | Oct 2006 | JP |
2007501099 | Jan 2007 | JP |
2007510447 | Apr 2007 | JP |
2008536633 | Sep 2008 | JP |
2013248530 | Dec 2013 | JP |
2004105871 | Dec 2004 | WO |
2009111764 | Sep 2009 | WO |
2009111766 | Sep 2009 | WO |
2009137726 | Nov 2009 | WO |
Entry |
---|
Gunderson et al. “An Algorithm to Predict Implantable Cardioverter-Defibrillator Lead Failure.” JACC, 44:9, pp. 1898-1902, Nov. 2004. |
Olson et al. “Onset and Stability for Ventricular Tachyarrhythmia Detection in an Implantable Pacer-Cardioverter-Defibrillator,” IEEE, pp. 167-170, 1987. |
“QT Interval,” Wikipedia, [Online]. Retrieved from the Internet: <URL: http://en.wikipedia.org/wiki/QT_interval>, (Accessed May 11, 2011), 5 pgs. |
Schuder, “The Role of an Engineering Oriented Medical Research Group in Developing Improved Methods and Devices for Achieving Ventricular Defibrillation: The University of Missouri Experience.” PACE, vol. 16, pp. 95-124, Jan. 1993. |
Schwake et al., “Komplikationen nit Sonden bei 340 Patienten mit einem Implantierbaren Kardioverter/Defibrillator.” Z Kardiol, 88:8, pp. 559-565, 1999. |
Swerdlow et al., “Advanced ICD Troubleshooting: Part I.” PACE, vol. 28, [Online]. Retrieved from the Internet: <http://www.medscape.com/viewarticle/520588_print>, pp. 1322-1346, Jan. 9, 2006. |
Throne et al., “A Comparison of Four New Time-Domain Techniques for Discriminating Monomorphic Ventricular Tachycardia from Sinus Rhythm Using Ventricular Waveform Morphology.” IEEE Transactions on Biomedical Engineering, vol. 38(6), pp. 561-570, Jun. 1991. |
Von Dem Wildenberg et al., “Biotransformation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1-H-dibenz [2,3:6,7]oxepin o [4,5-c]pyrrolidine maleate in rats,” Arzneimittelforschung, vol. 40(5), pp. 540-544, May 1990. |
Number | Date | Country | |
---|---|---|---|
20170095175 A1 | Apr 2017 | US |
Number | Date | Country | |
---|---|---|---|
62037288 | Aug 2014 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14815267 | Jul 2015 | US |
Child | 15384144 | US |